IP Library › Granted Patent US 12,208,164
Granted Patent B2
US 12,208,164 · App. 17/434,363 · Granted Jan 28, 2025

Modular metal-organic polyhedra superassembly compositions

Inventors: C. Jeffrey Brinker (Albuquerque, NM); Jimin Guo (Albuquerque, NM); Wei Zhu (Albuquerque, NM)
Assignee: UNM Rainforest Innovations
A61K9/1075A61K31/704A61K33/242A61K47/10A61K47/24A61K47/6849A61K47/6907A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,164
App. No.
17/434,363
Granted
Jan 28, 2025
Kind
B2
Abstract

A method to prepare a population of metal-organic polyhedra (MOP) supported micelle nanoparticles (NPs), and a composition comprising MOP supported micelle NPs, are provided.

Claims (22)

1. A method to prepare a population of metal-organic polyhedra (MOP) supported micelle nanoparticles (NPs), comprising:

combining an amount of metal and an amount of an organic ligand comprising one or more hydrophobic chains under conditions to form a population of metal-organic polyhedra units; and

combining an amount of the population of metal-organic polyhedra units and an amount of a micellar solution under conditions to form single MOP-supported micelle nanoparticles (NPs).

2. The method of claim 1 wherein the metal is palladium, copper, zinc, platinum, manganese or beryllium.

3. The method of claim 1 wherein the hydrophobic chain is a C1-C20 alkyl chain.

4. The method of claim 1 wherein the ligand comprises a carboxylate, such as 1 , 4 -benzenedicarboxylic, heterocyclic azolate, pyridine, thiophene, furan, pyrrole, or cyanide.

5. The method of claim 1 wherein the conditions to form single MOP-supported micelle nanoparticles comprise sonication.

6. The method of claim 1 wherein the conditions to form metal-organic polyhedra units yield a precipitate.

7. The method of claim 1 wherein the conditions to form metal-organic polyhedra units comprise applying heat.

8. The method of claim 1 wherein the diameter of the metal-organic polyhedra unit is from about 1 nm to about 15 nm, about 10 nm to about 25 nm or about 3 nm to about 10 nm.

9. The method of claim 1 wherein the diameter of the micelle is from about 10 nm to about 25 nm, 10 nm to about 20 nm about 15 nm to about 25 nm, about 100 nm to about 800 nm, about 200 nm to about 500 nm, about 500 nm to about 900 nm, about 1000 nm to about 3000 nm or about 1500 nm to about 2500 nm.

10. The method of claim 1 wherein the micelle solution comprises PEG, DSPE, or combination thereof.

11. The method of claim 10 wherein the PEG has 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 PEO units.

12. The method of claim 1 further comprising forming superassemblies of the micelle.

13. The method of claim 1 wherein the MOP-supported micelle nanoparticles further comprise one or more cargo or targeting molecules.

14. The method of claim 13 wherein the one or more cargo molecules comprise a drug, a dye a contrast agent, an antibody or a fragment thereof, a protein ligand, a quantum dot or a gold nanoparticle.

15. A population of single MOP-supported micelle nanoparticles prepared by the method of claim 1 .

16. A population of superassemblies of metal-organic polyhedral prepared by the method of claim 12 .

17. A method to prevent, inhibit or treat cancer, to deliver a drug or for imaging in a mammal, comprising: administering to the mammal an effective amount of a composition comprising the population of claim 15 which comprises drugs or an imaging agent.

18. A support comprising the population of claim 15 .

19. The support of claim 18 which is a membrane.

20. A micelle comprising a plurality of metal-organic polyhedral units having metal nodes and an organic ligand comprising one or more hydrophobic chains.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2024
From: BRINKER, C. JEFFREY; GUO, JIMIN; ZHU, WEI
To: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO
Reel/Frame 068878/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2024
From: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO
To: UNM RAINFOREST INNOVATIONS
Reel/Frame 068878/0404 →
Continuity (2)
Provisional Application 62811668 · Feb 28, 2019
Related Publication 20220151924A1 · May 19, 2022
References Cited (400)
US 4927637A · Morano et al. · 1990 [cited by applicant]
US 5057296A · Beck · 1991 [cited by applicant]
US 5098684A · Kresge et al. · 1992 [cited by applicant]
US 5360834A · Popall et al. · 1994 [cited by applicant]
US 5689574A · Heirich et al. · 1997 [cited by applicant]
US 5789230A · Cotten · 1998 [cited by applicant]
US 6194388B1 · Krieg et al. · 2001 [cited by applicant]
US 6365266B1 · MacDougall et al. · 2002 [cited by applicant]
US 6387453B1 · Brinker et al. · 2002 [cited by applicant]
US 6808867B2 · Doshi et al. · 2004 [cited by applicant]
US 6913832B2 · Fan et al. · 2005 [cited by applicant]
US 7101967B2 · Fischer et al. · 2006 [cited by applicant]
US 7332264B2 · Doshi et al. · 2008 [cited by applicant]
US 7514267B1 · Lopez et al. · 2009 [cited by applicant]
US 7563451B2 · Lin et al. · 2009 [cited by applicant]
US 8268962B2 · Heemskerk et al. · 2012 [cited by applicant]
US 8374816B2 · Vu · 2013 [cited by applicant]
US 8734816B2 · Liu et al. · 2014 [cited by applicant]
US 8926994B2 · Serda et al. · 2015 [cited by applicant]
US 8992984B1 · Brinker et al. · 2015 [cited by applicant]
US 9480653B2 · Brinker et al. · 2016 [cited by applicant]
US 9579283B2 · Brinker et al. · 2017 [cited by applicant]
US 9855217B2 · Brinker et al. · 2018 [cited by applicant]
US 9989447B1 · Kaehr et al. · 2018 [cited by applicant]
US 10022327B2 · Brinker et al. · 2018 [cited by applicant]
US 10465189B2 · Venkatraman et al. · 2019 [cited by applicant]
US 11344629B2 · Brinker et al. · 2022 [cited by applicant]
US 11672866B2 · Durfee et al. · 2023 [cited by applicant]
US 20020147105A1 · Shamshoum et al. · 2002 [cited by applicant]
US 20040005352A1 · Lopez et al. · 2004 [cited by applicant]
US 20040258671A1 · Watkins · 2004 [cited by applicant]
US 20050239687A1 · Divita et al. · 2005 [cited by applicant]
US 20060154069A1 · Lin et al. · 2006 [cited by applicant]
US 20070224257A1 · Commander et al. · 2007 [cited by applicant]
US 20070287104A1 · Doshi et al. · 2007 [cited by applicant]
US 20070298093A1 · Konur et al. · 2007 [cited by applicant]
US 20080095852A1 · Kong et al. · 2008 [cited by applicant]
US 20080160313A1 · Lopez et al. · 2008 [cited by applicant]
US 20080213377A1 · Bhatia et al. · 2008 [cited by applicant]
US 20080241262A1 · Lee et al. · 2008 [cited by applicant]
US 20080241917A1 · Akita et al. · 2008 [cited by applicant]
US 20080286371A1 · Pacheco et al. · 2008 [cited by applicant]
US 20090054246A1 · Peabody et al. · 2009 [cited by applicant]
US 20090170931A1 · Faulds et al. · 2009 [cited by applicant]
US 20090181090A1 · Dreis et al. · 2009 [cited by applicant]
US 20090208563A1 · Watkins et al. · 2009 [cited by applicant]
US 20090291131A1 · Maclachlan et al. · 2009 [cited by applicant]
US 20090305409A1 · Kogure et al. · 2009 [cited by applicant]
US 20100028341A1 · Hermans et al. · 2010 [cited by applicant]
US 20100055167A1 · Zhang et al. · 2010 [cited by applicant]
US 20100152699A1 · Ferrari et al. · 2010 [cited by applicant]
US 20100166665A1 · Butts et al. · 2010 [cited by applicant]
US 20100166808A1 · Pauletti et al. · 2010 [cited by applicant]
US 20100168120A1 · Watterson et al. · 2010 [cited by applicant]
US 20100255103A1 · Liong et al. · 2010 [cited by applicant]
US 20110059156A9 · Mirkin et al. · 2011 [cited by applicant]
US 20110097819A1 · Groves et al. · 2011 [cited by applicant]
US 20110135571A1 · Lin et al. · 2011 [cited by applicant]
US 20110230372A1 · Willman et al. · 2011 [cited by applicant]
US 20110268791A1 · Liu et al. · 2011 [cited by applicant]
US 20110300186A1 · Hellstrom et al. · 2011 [cited by applicant]
US 20120207795A1 · Zink et al. · 2012 [cited by applicant]
US 20130095039A1 · Lu et al. · 2013 [cited by applicant]
US 20130108661A1 · Blander et al. · 2013 [cited by applicant]
US 20130115169A1 · Lahann et al. · 2013 [cited by applicant]
US 20130122054A1 · Harashima et al. · 2013 [cited by applicant]
US 20130185823A1 · Kuang et al. · 2013 [cited by applicant]
US 20130195963A1 · Serda et al. · 2013 [cited by applicant]
US 20130197103A1 · Brown · 2013 [cited by applicant]
US 20140023700A1 · Knudsen et al. · 2014 [cited by applicant]
US 20140079774A1 · Brinker et al. · 2014 [cited by applicant]
US 20140141089A1 · Liang · 2014 [cited by applicant]
US 20140212479A1 · Zeinelden · 2014 [cited by applicant]
US 20140234210A1 · Lin et al. · 2014 [cited by applicant]
US 20140301951A1 · Liu et al. · 2014 [cited by applicant]
US 20150010475A1 · Brinker et al. · 2015 [cited by applicant]
US 20150118247A1 · Hotson et al. · 2015 [cited by applicant]
US 20150125384A1 · Mellman et al. · 2015 [cited by applicant]
US 20150125391A1 · Swami et al. · 2015 [cited by applicant]
US 20150164798A1 · Brinker et al. · 2015 [cited by applicant]
US 20150272885A1 · Ashley et al. · 2015 [cited by applicant]
US 20150320681A1 · Brinker et al. · 2015 [cited by applicant]
US 20160008283A1 · Nel et al. · 2016 [cited by applicant]
US 20160090603A1 · Carnes et al. · 2016 [cited by applicant]
US 20160106671A1 · Brinker et al. · 2016 [cited by applicant]
US 20160151482A1 · Carnes et al. · 2016 [cited by applicant]
US 20160193588A1 · Haynes et al. · 2016 [cited by applicant]
US 20160287717A1 · Brinker · 2016 [cited by applicant]
US 20160338954A1 · Brinker · 2016 [cited by applicant]
US 20160361411A1 · Gindy et al. · 2016 [cited by applicant]
US 20170042870A1 · Xue et al. · 2017 [cited by applicant]
US 20170165375A1 · Ashley et al. · 2017 [cited by applicant]
US 20170232115A1 · Ashley et al. · 2017 [cited by applicant]
US 20180028686A1 · Brinker et al. · 2018 [cited by applicant]
US 20180049984A1 · Brinker et al. · 2018 [cited by applicant]
US 20180105430A1 · Carnes et al. · 2018 [cited by applicant]
US 20180110831A1 · Brinker et al. · 2018 [cited by applicant]
US 20180344641A1 · Brinker et al. · 2018 [cited by applicant]
US 20190022235A1 · Durfee et al. · 2019 [cited by applicant]
US 20190091150A1 · Brinker et al. · 2019 [cited by applicant]
US 20190262469A1 · Brinker et al. · 2019 [cited by applicant]
US 20190330373A1 · Stephan · 2019 [cited by applicant]
US 20200009264A1 · Brinker et al. · 2020 [cited by applicant]
US 20200197536A1 · Brinker et al. · 2020 [cited by applicant]
US 20200375912A1 · Serda et al. · 2020 [cited by applicant]
US 20200405650A1 · Noureddine et al. · 2020 [cited by applicant]
US 20210030675A1 · Brinker et al. · 2021 [cited by applicant]
US 20210315822A1 · Guo et al. · 2021 [cited by applicant]
US 20220033767A1 · Guo et al. · 2022 [cited by applicant]
US 20220033768A1 · Guo et al. · 2022 [cited by applicant]
EP 1852393A1 · 2007 [cited by applicant]
JP 2009515520A · 2009 [cited by applicant]
WO WO9747296A2 · 1997 [cited by applicant]
WO WO0076556A2 · 2000 [cited by applicant]
WO WO02066506A2 · 2002 [cited by applicant]
WO WO03055469A1 · 2003 [cited by applicant]
WO WO2004096140A2 · 2004 [cited by applicant]
WO WO2005009602A2 · 2005 [cited by applicant]
WO WO2005084710A2 · 2005 [cited by applicant]
WO WO2007140618A1 · 2007 [cited by applicant]
WO WO2009051837A2 · 2009 [cited by applicant]
WO WO2010035304A2 · 2010 [cited by applicant]
WO WO2010048572A1 · 2010 [cited by applicant]
WO WO2010078569A2 · 2010 [cited by applicant]
WO WO2011116219A1 · 2011 [cited by applicant]
WO WO2011116226A2 · 2011 [cited by applicant]
WO WO2011150264A2 · 2011 [cited by applicant]
WO WO2012149376A2 · 2012 [cited by applicant]
WO WO2013012891A1 · 2013 [cited by applicant]
WO WO2013056132A2 · 2013 [cited by applicant]
WO WO2013082612A1 · 2013 [cited by applicant]
WO WO2013103614A1 · 2013 [cited by applicant]
WO WO2014093635A1 · 2014 [cited by applicant]
WO WO2014165608A1 · 2014 [cited by applicant]
WO WO2014165617A1 · 2014 [cited by applicant]
WO WO2015042268A1 · 2015 [cited by applicant]
WO WO2015042279A1 · 2015 [cited by applicant]
WO WO2015095340A1 · 2015 [cited by applicant]
WO WO2015130584A2 · 2015 [cited by applicant]
WO WO2016145031A1 · 2016 [cited by applicant]
WO WO2016145335A1 · 2016 [cited by applicant]
WO 2017013250 · 2017 [cited by applicant]
WO WO2017041032A1 · 2017 [cited by applicant]
WO WO2017041033A1 · 2017 [cited by applicant]
WO WO2017120504A1 · 2017 [cited by applicant]
WO WO2018000043A1 · 2018 [cited by applicant]
WO WO2018160865 · 2018 [cited by applicant]
WO WO2018187287A1 · 2018 [cited by applicant]
WO WO2019028387A1 · 2019 [cited by applicant]
WO WO2019169152A1 · 2019 [cited by applicant]
WO WO2020028342A1 · 2020 [cited by applicant]
WO WO2020068798A1 · 2020 [cited by applicant]
WO WO2020068806A1 · 2020 [cited by applicant]
WO WO2020176716A1 · 2020 [cited by applicant]
WO 2023147596 · 2023 [cited by applicant]
WO 2024182425 · 2024 [cited by applicant]
Zhu et al., Adv. Mater. 2019,31,1806774, 1-10 (published online Jan. 31, 2019). (Year: 2019). [cited by examiner]
“International Application Serial No. PCT/US2020/020066, International Search Report mailed Jun. 25, 2020”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/020066, Written Opinion mailed Jun. 25, 2020”, 4 pgs. [cited by applicant]
Mohamed, Salma, et al., “(Abstract) Polymeric nano-micelles: versatile platform for targeted delivery in cancer”, Ther. Deliv., vol. 5, No. 10, pp. 1101-1121, (Oct. 2014), 1 pg. [cited by applicant]
Mollick, Samraj, et al., “(Abstract) Outer Surface Hydrophobic Shielding Strategy to Enhance the Chemical Stability of Metal-Organic Polyhedra”, Angew Chem Int Ed Engl, vol. 58, No. 4, pp. 1041-1045, (Jan. 21, 2019), 1 … [cited by applicant]
Zhu, Wei, et al., “Modular Metal-Organic Polyhedra Superassambly: From Molecular-Level Design to Targeted Drug Delivery”, Adv. Mater., vol. 31, No. 12, 1806774, (Mar. 2019), 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/068,235, Notice of Allowance mailed Feb. 13, 2023”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/068,235, Notice of Allowance mailed Oct. 12, 2022”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/068,235, Supplemental Notice of Allowability mailed Feb. 21, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/068,235, Supplemental Notice of Allowability mailed Oct. 17, 2022”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/500,349, Final Office Action mailed May 3, 2023”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/500,349, Non Final Office Action mailed Nov. 30, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/500,349, Response filed Feb. 28, 2023 to Non Final Office Action mailed Nov. 30, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/500,349, Response filed Aug. 22, 2022 to Restriction Requirement mailed Jun. 22, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Advisory Action mailed Jan. 27, 2023”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Final Office Action mailed Sep. 19, 2022”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Non Final Office Action mailed Apr. 10, 2023”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Response filed Jan. 19, 2023 to Final Office Action mailed Sep. 19, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Response filed Mar. 17, 2023 to Advisory Action mailed Jan. 27, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Response filed Aug. 31, 2022 to Non Final Office Action mailed May 31, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Examiner Interview Summary mailed Jan. 27, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Non Final Office Action mailed Feb. 28, 2023”, 29 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Non Final Office Action mailed Nov. 2, 2022”, 37 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Response filed Feb. 1, 2023 to Non Final Office Action mailed Nov. 2, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Response filed Oct. 19, 2022 to Non Final Office Action mailed Jul. 19, 2022”, 10 pgs. [cited by applicant]
Berge, Stephen M, et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1), (Jan. 1977), 1-19. [cited by applicant]
Doshi, Nishit, et al., “Red blood cell-mimicking synthetic biomaterial particles”, PNAS, vol. 106, No. 51, (Dec. 22, 2009), 21495-21499. [cited by applicant]
Langley, P J, “Nanoporous and mesoporous organic structures: new openings for materials research”, Chemical Society Reviews, vol. 28, (1999), 279-291. [cited by applicant]
Maeder, Morgan L, et al., “CRISPR RNA-guided activation of endogenous human genes”, Nature Methods, vol. 10, No. 10, (2013), 977-979. [cited by applicant]
Merkel, Timothy J., et al., “Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles”, PNAS, vol. 108, No. 2, (Jan. 11, 2011), 586-591. [cited by applicant]
Qi, Lei S., et al., “Repurposing CRISPR as RNA-Guided Platform for Sequence-Specific Control of Gene Expression”, Cell, 152(5), (2013), 1-22. [cited by applicant]
Taylor, Erik N., et al., “Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer”, Int. J. Mol. Sci. 2022, 23(18), 10525, (Sep. 10, 2022), … [cited by applicant]
Wan, Chao, et al., “Activation of the hypoxia-inducible factor-1a pathway accelerates bone regeneration”, PNAS, vol. 105, No. 2, (2008), 686-691. [cited by applicant]
Wang, Zhen, et al., “Targeting p53 for Novel Anticancer Therapy”, Translational Oncology, vol. 3, No. 1, (2010), 1-12. [cited by applicant]
“U.S. Appl. No. 16/635,246, Advisory Action mailed Oct. 5, 2023”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Non Final Office Action mailed Nov. 1, 2023”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Response filed Sep. 25, 2023 to Final Office Action mailed Jul. 25, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 17/277,260, Restriction Requirement mailed Nov. 20, 2023”, 9 pgs. [cited by applicant]
Lee, Juno, et al., “Chemical sporulation and germination: cytoprotective nanocoating of individual mammalian cells with a degradable tannic acid-Fell I complex”, Nanoscale 7(45), (2015), 18918-18922. [cited by applicant]
Valentina, Colapicchioni, et al., “Killing cancer cells using nanotechnology: novel poly(I:C) loaded liposome-silica hybrid nanoparticles”, Journal of Materials Chemistry B, vol. 3, (2015), 7408-7416. [cited by applicant]
“International Application Serial No. PCT US2023 061675, International Search Report mailed May 24, 2023”, 6 pgs. [cited by applicant]
“International Application Serial No. PCT US2023 061675, Written Opinion mailed May 24, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Response filed Jun. 28, 2023 to Non Final Office Action mailed Feb. 28, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Response filed Jul. 10, 2023 to Non Final Office Action mailed Apr. 10, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/635,246, Final Office Action mailed Jul. 25, 2023”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 16/976,651, Final Office Action mailed Jul. 27, 2023”, 25 pgs. [cited by applicant]
Brinker, C J, “2021-023—Triplex Nanoparticles for Targeted Gene Delivery”, UNM Rainforest Innovations, [Online]. Retrieved from the Internet: https: unm.flintbox.com technologies c52813ba-2361-47e9-baca-e6f39303b3fd, (A… [cited by applicant]
Noureddine, A, “Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery”, Acta Biomaterialia, Epub. vol. 114, (Jul. 21, 2020), 358-368. [cited by applicant]
U.S. Appl. No. 09/838,153 U.S. Pat. No. 6,471,761, filed Apr. 20, 2001, Rapid Prototyping of Patterned Organic/Inorganic Functional Nanostructures. [cited by applicant]
U.S. Appl. No. 10/163,425 U.S. Pat. No. 6,913,832, filed Jun. 7, 2002, Prototyping of Patterned Functional Nanostructures. [cited by applicant]
U.S. Appl. No. 09/543,572, filed Apr. 5, 2000, Photo-Definable Self-Assembled Materials. [cited by applicant]
U.S. Appl. No. 10/100,108 U.S. Pat. No. 6,808,867, filed Mar. 19, 2002, Photo-Definable Self-Assembled Materials. [cited by applicant]
U.S. Appl. No. 10/373,565 U.S. Pat. No. 7,332,264, filed Feb. 26, 2003, Photo-Definable Self-Assembled Materials. [cited by applicant]
U.S. Appl. No. 09/389,085, filed Sep. 2, 1999, Low Frequency Feedback Speaker System. [cited by applicant]
U.S. Appl. No. 08/385,338, filed Feb. 8, 1995, Unidirectional Ring Laser Gyroscope. [cited by applicant]
U.S. Appl. No. 08/250,882 U.S. Pat. No. 5,438,585, filed May 31, 1994, Unstable Resonator Semiconductor Laser. [cited by applicant]
U.S. Appl. No. 16/500,349, filed Oct. 2, 2019, Porous Nanoparticle-Supported Lipid Bilayer Delivery of Transcriptional Gene Modulators. [cited by applicant]
U.S. Appl. No. 15/023,093, filed Mar. 18, 2016, Core and Surface Modification of Mesoporous Silica Nanoparticles to Achieve Cell Specific Targeting In Vivo. [cited by applicant]
U.S. Appl. No. 15/023,110 U.S. Pat. No. 9,855,217, filed Mar. 18, 2016, Toroidal Mesoporous Silica Nanoparticles (TMSNPS) and Related Protocells. [cited by applicant]
U.S. Appl. No. 15/858,923, filed Dec. 29, 2017, Toroidal Mesoporous Silica Nanoparticles (TMSNPS) and Related Protocells. [cited by applicant]
U.S. Appl. No. 14/350,674, filed May 20, 2014, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery Including Transdermal Delivery of Cargo and Methods Thereof. [cited by applicant]
U.S. Appl. No. 15/380,962, filed Dec. 15, 2016, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Delivery Including Transdermal Delivery of Cargo and Methods Thereof. [cited by applicant]
U.S. Appl. No. 14/781,765, filed Nov. 23, 2015, Mesoporous Alum Nanoparticles as a Universal Platform for Antigen Adsorption, Presentation, and Delivery. [cited by applicant]
U.S. Appl. No. 12/909,572 U.S. Pat. No. 8,992,984, filed Oct. 21, 2010, Protocells and Their Use for Targeted Delivery of Multicomponent Cargos to Cancer Cells. [cited by applicant]
U.S. Appl. No. 14/627,739 U.S. Pat. No. 9,480,653, filed Feb. 20, 2015, Protocells and Their Use for Targeted Delivery of Multicomponent Cargos to Cancer Cells. [cited by applicant]
U.S. Appl. No. 14/797,487, filed Jul. 13, 2015, Protocells and Their Use for Targeted Delivery of Multicomponent Cargos to Cancer Cells. [cited by applicant]
U.S. Appl. No. 14/113,371 U.S. Pat. No. 9,579,283, filed Dec. 4, 2013, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery and Methods of Using Same. [cited by applicant]
U.S. Appl. No. 14/970,998 U.S. Pat. No. 10,022,327, filed Dec. 16, 2015, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery and Methods of Using Same. [cited by applicant]
U.S. Appl. No. 16/025,557, filed Jul. 2, 2018, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery and Methods of Using Same. [cited by applicant]
U.S. Appl. No. 14/781,817, filed Nov. 9, 2015, Antibiotic Protocells and Related Pharmaceutical Formulations and Methods of Treatment. [cited by applicant]
U.S. Appl. No. 15/474,800, filed Mar. 30, 2017, Protocells for Plasmid and RNP Delivery in the Treatment of Cancer and Other Disease States. [cited by applicant]
U.S. Appl. No. 15/474,810, filed Mar. 30, 2017, Carriers for Plasmid and RNP Delivery in the Treatment of Cancer and Other Disease States. [cited by applicant]
U.S. Appl. No. 14/369,741, filed Jun. 30, 2014, CRLF-2 Binding Peptides, Protocells and Viral-Like Particles Useful in the Treatment of Cancer, Including Acute Lymphoblastic Leukemia (ALL). [cited by applicant]
U.S. Appl. No. 15/788,634, filed Oct. 19, 2017, CRLF-2 Binding Peptides, Protocells And Viral-Like Particles Useful in the Treatment of Cancer, Including Acute Lymphoblastic Leukemia (ALL). [cited by applicant]
U.S. Appl. No. 13/143,164 U.S. Pat. No. 8,734,816, filed Jul. 1, 2011, Porous Nanoparticle Supported Lipid Bilayer Nanostructures. [cited by applicant]
U.S. Appl. No. 14/253,030, filed Apr. 15, 2014, Porous Nanoparticle Supported Lipid Nanostructures. [cited by applicant]
U.S. Appl. No. 15/557,368, filed Sep. 11, 2017, Generation of Mesoporous Materials Using Multiphase Surfactant Systems. [cited by applicant]
U.S. Appl. No. 12/903,577, filed Oct. 13, 2010, Protocells and Their Use for Pain Treatment. [cited by applicant]
U.S. Appl. No. 15/757,254, filed Mar. 2, 2018, Protocells to Treat Microbial Infection and for Synergistic Delivery. [cited by applicant]
U.S. Appl. No. 15/757,269, filed Mar. 2, 2018, Mesoporous Silica Nanoparticles and Supported Lipid Bi-Layer Nanoparticles for Biomedical Applications. [cited by applicant]
U.S. Appl. No. 16/828,137, filed Mar. 24, 2020, Mesoporous Silica Nanoparticles and Supported Lipid Bi-Layer Nanoparticles for Biomedical Applications. [cited by applicant]
U.S. Appl. No. 15/557,000, filed Sep. 8, 2017, CD 47 Containing Porous Nanoparticle Supported Lipid Bilayers (Protocells) Field of the Invention. [cited by applicant]
U.S. Appl. No. 16/068,235, filed Jul. 5, 2018, Osteotropic Nanoparticles for Prevention or Treatment of Bone Metastases. [cited by applicant]
U.S. Appl. No. 16/490,280 U.S. Pat. No. 11,344,629, filed Aug. 30, 2019, Active Targeting of Cells by Monosized Protocells. [cited by applicant]
U.S. Appl. No. 16/635,246, filed Jan. 30, 2020, Liposomal Coated Nanoparticles for Immunotherapy Applications. [cited by applicant]
U.S. Appl. No. 15/887,619, filed Feb. 2, 2018, Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Delivery Including Transdermal Delivery of Cargo and Methods Thereof. [cited by applicant]
U.S. Appl. No. 16/976,651, filed Aug. 28, 2020, Starry Mesoporous Silica Nanoparticles and Supported Lipid Bi-Layer Nanoparticles. [cited by applicant]
U.S. Appl. No. 17/264,452, filed Jan. 29, 2021, Biomimetic Rebuilding of Multifunctional Red Blood Cells. [cited by applicant]
U.S. Appl. No. 17/277,256, filed Mar. 17, 2021, Living Mammalian Cells Modified With Functional Modular Nanoparticles. [cited by applicant]
U.S. Appl. No. 17/277,260, filed Mar. 17, 2021, Armored Cells. [cited by applicant]
“U.S. Appl. No. 10/100,108, Non Final Office Action mailed Jan. 22, 2004”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 10/100,108, Notice of Allowance mailed Jul. 13, 2004”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 10/100,108, Response filed Apr. 21, 2004 to Non Final Office Action mailed Jan. 22, 2004”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Advisory Action mailed Jul. 2, 2004”. [cited by applicant]
“U.S. Appl. No. 10/163,425, Examiner Interview Summary filed Mar. 29, 2005”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Final Office Action mailed Mar. 31, 2004”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Non Final Office Action mailed Aug. 1, 2003”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Non Final Office Action mailed Sep. 22, 2004”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Notice of Allowance mailed Feb. 10, 2005”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Response filed Jan. 2, 2004 to Non Final Office Action mailed Aug. 1, 2003”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Response filed May 28, 2004 to Final Office Action mailed Mar. 31, 2004”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Response filed Jul. 23, 2004 to Advisory Action mailed Jul. 2, 2004”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 10/163,425, Response filed Dec. 22, 2004 to Non Final Office Action mailed Sep. 22, 2004”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 10/373,565, Notice of Allowance mailed Sep. 11, 2007”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Advisory Action mailed Mar. 20, 2012”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Advisory Action mailed Jun. 7, 2017”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Final Office Action mailed May 8, 2015”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Final Office Action mailed Nov. 30, 2011”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Non Final Office Action mailed Jun. 3, 2014”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Non Final Office Action mailed Jun. 30, 2011”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Non Final Office Action mailed Oct. 25, 2017”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Notice of Non-Compliant Amendment mailed Feb. 4, 2015”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Jan. 20, 2016 to Final Office Action mailed May 8, 2015”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Feb. 26, 2015 to Notice of Non-Compliant Amendment mailed Feb. 4, 2015”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Mar. 9, 2012 to Final Office Action mailed Nov. 30, 2011”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Jun. 1, 2011 to Restriction Requirement mailed May 13, 2011”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Jul. 12, 2017 to Advisory Action mailed Jul. 7, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Sep. 30, 2011 to Non Final Office Action mailed Jun. 30, 2011”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Response filed Dec. 3, 2014 to Non Final Office Action mailed Jun. 3, 2014”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 12/903,577, Restriction Requirement mailed May 13, 2011”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, 312 Amendment filed Mar. 27, 2014”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Final Office Action mailed Jun. 26, 2013”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Non Final Office Action mailed Jan. 11, 2013”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Notice of Allowance mailed Jan. 13, 2014”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Response filed Apr. 10, 2013 to Non Final Office Action mailed Jan. 11, 2013”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Response filed Nov. 7, 2012 to Restriction Requirement mailed Oct. 10, 2012”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Response filed Nov. 26, 2013 to Final Office Action mailed Jun. 26, 2013”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 13/143,164, Restriction Requirement mailed Oct. 10, 2012”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, 312 Amendment filed Dec. 21, 2016”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Amendment filed Sep. 23, 2016”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Examiner Interview Summary mailed Mar. 25, 2016”, 1 pg. [cited by applicant]
“U.S. Appl. No. 14/113,371, Final Office Action mailed Feb. 1, 2016”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Final Office Action mailed Mar. 25, 2016”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Non Final Office Action mailed Jul. 13, 2015”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Non Final Office Action mailed Dec. 17, 2014”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Notice of Allowability mailed Jan. 31, 2017”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Notice of Allowance mailed Oct. 11, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Preliminary Amendment filed Oct. 22, 2013”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Response filed Apr. 16, 2015 to Non Final Office Action mailed 12-17-1”, 23 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Response filed Aug. 25, 2016 to Final Office Action mailed Mar. 25, 2016”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Response filed Oct. 17, 2014 to Restriction Requirement mailed Aug. 18, 2014”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Response filed Nov. 4, 2015 to Non Final Office Action mailed Jul. 13, 2015”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Response filed Sep. 26, 2016 to Final Office Action mailed Mar. 25, 2016”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/113,371, Restriction Requirement mailed Aug. 18, 2014”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Advisory Action mailed Apr. 11, 2018”, 25 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Advisory Action mailed Sep. 5, 2017”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Advisory Action mailed Sep. 9, 2016”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Declaration under 37 C.F.R 1.132 filed Mar. 27, 2018”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Final Office Action mailed May 11, 2016”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Final Office Action mailed Jun. 9, 2017”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Final Office Action mailed Dec. 1, 2017”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Non Final Office Action mailed Dec. 9, 2016”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Non Final Office Action mailed Dec. 10, 2015”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Preliminary Amendment filed Jul. 1, 2015”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Preliminary Amendment filed Dec. 9, 2014”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Mar. 10, 2016 to Non Final Office Action mailed Dec. 10, 2015”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Aug. 11, 2016 to Final Office Action mailed May 11, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Oct. 10, 2017 to Advisory Action mailed Sep. 5, 2017”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Oct. 11, 2016 to Advisory Action mailed Sep. 9, 2016”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Nov. 2, 2015 to Restriction Requirement mailed Oct. 6, 2015”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Apr. 2, 2018 to Final Office Action mailed Dec. 1, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed May 9, 2017 to Non-Final Office ACtion mailed Dec. 9, 2016”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Response filed Aug. 10, 2017 to Final Office Action mailed Jun. 9, 2017”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Restriction Requirement mailed Sep. 17, 2015”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Restriction Requirement mailed Oct. 6, 2015”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/253,030, Supplemental Declaration under 37 C.F.R. 1.132 filed Aug. 7, 2017”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 14/350,674, Non Final Office Action mailed Jun. 17, 2016”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 14/350,674, Preliminary Amendment filed Jun. 4, 2015”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/350,674, Response filed May 16, 2016 to Restriction Requirement mailed Mar. 14, 2016”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/350,674, Restriction Requirement mailed Mar. 14, 2016”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Final Office Action mailed Apr. 19, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Non Final Office Action mailed Aug. 22, 2016”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Non Final Office Action mailed Nov. 23, 2015”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Preliminary Amendment filed Jun. 26, 2014”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Response filed Mar. 23, 2016 to Non Final Office Action mailed Nov. 23, 2015”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Response filed Sep. 14, 2015 to Restriction Requirement mailed May 14, 2015”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Response filed Dec. 22, 2016 to Non-Final Office Action mailed Aug. 22, 2016”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/369,741, Restriction Requirement mailed May 14, 2015”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Non Final Office Action mailed Jan. 29, 2016”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Notice of Allowance mailed Jul. 6, 2016”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Preliminary Amendment filed Feb. 20, 2015”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Response filed Apr. 15, 2016 to Non Final Office Action mailed Jan. 29, 2016”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Response filed Nov. 5, 2015 to Restriction Requirement mailed Aug. 6, 2015”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/627,739, Restriction Requirement mailed Aug. 6, 2015”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Advisory Action mailed Jan. 29, 2019”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Final Office Action mailed Aug. 28, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Non Final Office Action mailed Feb. 15, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Non Final Office Action mailed Jul. 15, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Response filed Jan. 21, 2019 to Final Office Action mailed Aug. 28, 2018”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Response filed Jun. 15, 2018 to Non Final Office Action mailed Feb. 15, 2018”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Response filed Jan. 24, 2018 to Restriction Requirement mailed Aug. 24, 2017”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Response filed Jan. 28, 2019 to Non-Final Office Action mailed Aug. 28, 2018”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,765, Restriction Requirement mailed Aug. 24, 2017”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,817, Preliminary Amendment filed Jan. 17, 2017”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,817, Restriction Requirement mailed Oct. 31, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,817, Supplemental Preliminary Amendment field Aug. 8, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/781,817, Supplemental Preliminary Amendment filed Jun. 27, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/797,487, Non Final Office Action mailed Jun. 14, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 14/797,487, Preliminary Amendment filed Jul. 24, 2015”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/797,487, Response filed Mar. 3, 2017 to Restriction Requirement mailed Jan. 3, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 14/797,487, Restriction Requirement mailed Jan. 3, 2017”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Final Office Action mailed Sep. 27, 2017”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Non Final Office Action mailed Apr. 6, 2017”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Notice of Allowance mailed Mar. 16, 2018”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Preliminary Amendment filed Dec. 16, 2015”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Preliminary Amendment filed Dec. 28, 2015”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Response filed Feb. 27, 2018 to Final Office Action mailed Sep. 27, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Response filed Mar. 17, 2017 to Restriction Requirement mailed Jan. 19, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Response filed Aug. 7, 2017 to Non-Final Office Action mailed Apr. 6, 2017”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 14/970,998, Restriction Requirement mailed Jan. 19, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,093 Response filed Feb. 3, 2017 to Restriction Requirement mailed Nov. 3, 2016”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,093, Non Final Office Action mailed Apr. 11, 2017”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,093, Preliminary Amendment filed Mar. 18, 2016”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,093, Restriction Requirement mailed Nov. 3, 2016”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Corrected Notice of Allowance mailed Sep. 5, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Non Final Office Action mailed Feb. 24, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Notice of Allowance mailed Aug. 21, 2017”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Preliminary Amendment filed Mar. 18, 2016”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Preliminary Amendment filed Jul. 5, 2016”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/023,110, Response filed Jul. 24, 2017 to Non-Final Office Action mailed Feb. 24, 2017”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/380,962, Non Final Office Action mailed Aug. 2, 2017”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 15/380,962, Preliminary Amendment filed Dec. 15, 2016”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 15/380,962, Response filed Jul. 19, 2017 to Restriction Requirement mailed May 18, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/380,962, Restriction Requirement mailed May 18, 2017”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Final Office Action mailed Mar. 8, 2019”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Non Final Office Action mailed Oct. 18, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Preliminary Amendment filed Jul. 19, 2017”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Preliminary Amendment filed Oct. 10, 2017”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Response filed Jan. 18, 2019 t Non-Final Office Action mailed Oct. 18, 2019”, 11 pg. [cited by applicant]
“U.S. Appl. No. 15/474,800, Response filed Aug. 13, 2018 to Restriction Requirement mailed Mar. 12, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,800, Restriction Requirement mailed Mar. 12, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Final Office Action mailed Mar. 8, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Non Final Office Action mailed Sep. 20, 2018”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Preliminary Amendment filed Jul. 18, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Response filed Jan. 18, 2019 to Non-Final Office Action mailed Sep. 20, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Response filed Aug. 7, 2018 to Restriction Requirement mailed Mar. 7, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810, Restriction Requirement mailed Mar. 7, 2018”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/474,810. Supplemental Preliminary Amendment filed Oct. 30, 2017”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 15/557,000, Preliminary Amendment filed Sep. 8, 2017”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/557,000, Restriction Requirement mailed Mar. 11, 2019”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 15/557,368, Preliminary Amendment filed Sep. 11, 2017”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/557,368, Restriction Requirement mailed Feb. 15, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 15/757,254, Preliminary Amendment filed Mar. 2, 2018”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 15/757,254, Restriction Requirement mailed Sep. 16, 2019”, 11 pgs. [cited by applicant]